Company intelligence / Profile preview
Whitehawk Therapeutics, Inc.
Morristown, New Jersey, United Statesaadibio.com ↗
- Ownership
- Public · WHWK
- Employees
- ~40
- Development stage
- Preclinical
01
Overview
Whitehawk Therapeutics is developing three ADC assets currently in preclinical stage. The company plans to submit three IND applications within the next 12-24 months, with the first submission expected in the second half of 2025[7].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-Drug Conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
WuXi BiologicsHANGZHOU DAC
04
Financials
- Market cap
- $232M
- Total revenue
- $0
- Enterprise value
- $42M
Beyond the preview
Go deeper on Whitehawk Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Whitehawk Therapeutics, Inc..